centers for disease control and prevention (U.S.)

Each year in the United States an estimated 9 million people get sick, 56,000 are hospitalized, and 1,300 die of foodborne disease caused by known pathogens. These estimates help us understand the scope of this public health problem. However, to develop effective prevention measures, we need to understand the types of foods contributing to the problem. The Interagency Food Safety Analytics Collaboration (IFSAC) is a tri-agency group created by the Centers for Disease Control and Prevention (CDC), the U.S. Food and Drug Administration (FDA), and the U.S. Department of Agriculture’s Food Safety and Inspection Service (USDA-FSIS). IFSAC developed a method to estimate the percentages of foodborne illness attributed to certain sources using outbreak data from 1998 through the most recent year for four priority pathogens: Salmonella, Escherichia coli O157, Listeria monocytogenes, and Campylobacter. IFSAC described this method and the estimates for 2012 in a report, peer-reviewed journal article, and at a public meeting. IFSAC derived the estimates for 2018 using the same method used for the 2012 estimates, with some modifications. The data came from 1,459 foodborne disease outbreaks that occurred from 1998 through 2018 and for which each confirmed or suspected implicated food was assigned to a single food category. The method relies most heavily on the most recent five years of outbreak data (2014 – 2018). Foods are categorized using a scheme IFSAC created that classifies foods into 17 categories that closely align with the U.S. food regulatory agencies’ classification needs

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season

Brian Desmarais — Mon, 30 Sep 2019 13:16:17 +0000

Date Added:

September 30, 2019

Journal/Publication:

Morbidity and Mortality Weekly Report

Publication Date:

August 23, 2019

Issue:

Volume:

Pages:

1-21

URL:

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Seaso

Type:

Public Health Announcements

Format:

Article

DOI (1):

10.15585/mmwr.rr6803a1

Keywords

Flu vaccines

vaccination recommendations

Centers for Disease Control and Prevention

MeSH

vaccines, inactivated

Hemagglutinins

Influenza A Virus, H1N1 Subtype

Influenza A Virus, H3N2 Subtype

united states food and drug administration

centers for disease control and prevention (U.S.)

Contraindications

This year’s flu vaccine recommendations from the CDC. James W. Mold, MD, MPH

Free full text

View

Abstract

This report updates the 2018-19 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2018;67[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. A licensed, recommended, and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV), and live attenuated influenza vaccine (LAIV) are expected to be available for the 2019-20 season. Standard-dose, unadjuvanted, inactivated influenza vaccines will be available in quadrivalent formulations (IIV4s). High-dose (HD-IIV3) and adjuvanted (aIIV3) inactivated influenza vaccines will be available in trivalent formulations. Recombinant (RIV4) and live attenuated influenza vaccine (LAIV4) will be available in quadrivalent formulations.Updates to the recommendations described in this report reflect discussions during public meetings of ACIP held on October 25, 2018; February 27, 2019; and June 27, 2019. Primary updates in this report include the following two items. First, 2019-20 U.S. trivalent influenza vaccines will contain hemagglutinin (HA) derived from an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A/Kansas/14/2017 (H3N2)-like virus, and a B/Colorado/06/2017-like virus (Victoria lineage). Quadrivalent influenza vaccines will contain HA derived from these three viruses, and a B/Phuket/3073/2013-like virus (Yamagata lineage). Second, recent labeling changes for two IIV4s, Afluria Quadrivalent and Fluzone Quadrivalent, are discussed. The age indication for Afluria Quadrivalent has been expanded from ≥5 years to ≥6 months. The dose volume for Afluria Quadrivalent is 0.25 mL for children aged 6 through 35 months and 0.5 mL for all persons aged ≥36 months (≥3 years). The dose volume for Fluzone Quadrivalent for children aged 6 through 35 months, which was previously 0.25 mL, is now either 0.25 mL or 0.5 mL. The dose volume for Fluzone Quadrivalent is 0.5 mL for all persons aged ≥36 months (≥3 years).This report focuses on the recommendations for use of vaccines for the prevention and control of influenza during the 2019-20 season in the United States. A brief summary of these recommendations and a Background Document containing additional information are available at https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html. These recommendations apply to U.S.-licensed influenza vaccines used within Food and Drug Administration-licensed indications. Updates and other information are available from CDC's influenza website (https://www.cdc.gov/flu). Vaccination and health care providers should check this site periodically for additional information.

Author/s:

Grohskopf, L.A., Alyanak, E., Broder, K.R., Walter, E.B., Fry, A.M., Jernigan, D.B.

Severe Pulmonary Disease Associated with Electronic-Cigarette–Product Use — Interim Guidance

John Bayhi — Fri, 13 Sep 2019 12:52:13 +0000

Date Added:

September 13, 2019

Journal/Publication:

Morbidity and Mortality Weekly Report

Publisher:

U.S. Department of Health & Human Services / Centers for Disease Control and Prevention

Publication Date:

September 13, 2019

Issue:

Volume:

Pages:

787-790

URL:

Severe Pulmonary Disease Associated with Electronic-Cigarette–Product Use — Interim Guidance

Type:

Public Health Announcements

Format:

Article

DOI (1):

10.15585/mmwr.mm6836e2

Keywords

PMID (1):

31513561

MeSH

electronic nicotine delivery systems

volatile organic compounds

Neoplasms

Lung Diseases

centers for disease control and prevention (U.S.)

The latest information from the CDC on lung disease associated with vaping. James W. Mold, MD, MPH

Free full text

View

On September 6, 2019, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). As of August 27, 2019, 215 possible cases of severe pulmonary disease associated with the use of electronic cigarette (e-cigarette) products (e.g., devices, liquids, refill pods, and cartridges) had been reported to CDC by 25 state health departments. E-cigarettes are devices that produce an aerosol by heating a liquid containing various chemicals, including nicotine, flavorings, and other additives (e.g., propellants, solvents, and oils). Users inhale the aerosol, including any additives, into their lungs. Aerosols produced by e-cigarettes can contain harmful or potentially harmful substances, including heavy metals such as lead, volatile organic compounds, ultrafine particles, cancer-causing chemicals, or other agents such as chemicals used for cleaning the device (1). E-cigarettes also can be used to deliver tetrahydrocannabinol (THC), the principal psychoactive component of cannabis, or other drugs; for example, "dabbing" involves superheating substances that contain high concentrations of THC and other plant compounds (e.g., cannabidiol) with the intent of inhaling the aerosol. E-cigarette users could potentially add other substances to the devices. This report summarizes available information and provides interim case definitions and guidance for reporting possible cases of severe pulmonary disease. The guidance in this report reflects data available as of September 6, 2019; guidance will be updated as additional information becomes available.

Author/s:

Schier, JG, Meiman, JG, Layden, J, Mikosz, CA, VanFrank, B, King, BA, Salvatore, PP, Weissman, DN, Thomas, J, Melstrom, PC, Baldwin, GT, Parker, EM, Courtney-Long, EA, Krishnasamy, VP, Pickens, CM, Evans, ME, Tsay, SV, Powell, KM, Kiernan, EA, Marynak, KL, Adjemian, J, Holton, K, Armour, BS, England, LJ, Briss, PA, Houry, D, Hacker, KA, Reagan-Steiner, S, Zaki, S, Meaney-Delman, D, CDC 2019 Lung Injury Response Group

ACIP Approves New Guidance on HPV, Pneumococcal Vaccines

Brian Desmarais — Wed, 10 Jul 2019 00:22:03 +0000

Date Added:

July 9, 2019

Journal/Publication:

American Academy of Family Physicians

Publication Date:

July 3, 2019

URL:

ACIP Approves New Guidance on HPV, Pneumococcal Vaccines

Type:

Public Health Announcements

Format:

Web Page

Keywords

MeSH

Neisseria meningitidis, Serogroup B

Pneumococcal Vaccines

centers for disease control and prevention (U.S.)

The Advisory Committee on Immunization Practices have updated their recommendations regarding HPV vaccine in adults 27-45 (shared decision-making), PCV 13 vaccine in adults 65 and older (shared decision-making), and Meningococcal B vaccine (booster dose after 1 – 2 years in immunocompromised children).

Free full text

View

July 03, 2019 03:21 pm Chris Crawford – During the June 26-27 meeting(www.cdc.gov) of the CDC's Advisory Committee on Immunization Practices, the group voted to update its recommendations for use of the nine-valent HPV and 13-valent pneumococcal conjugate vaccines.

AAFP liaison to the ACIP Pamela Rockwell, D.O., of Ann Arbor, Mich., told AAFP Newsother topics considered during the meeting included recommendations for a catch-up schedule for children and adolescents ages 2-18 who hadn't previously received hepatitis A vaccine, as well as guidance for serogroup B meningococcal vaccination boosters for those with special conditions/circumstances.

Author/s:

Crawford, C.

Acute Flaccid Myelitis Investigation

Jeffrey Wilson — Wed, 10 Oct 2018 16:48:11 +0000

Date Added:

October 10, 2018

Publication Date:

October 5, 2018

URL:

Acute Flaccid Myelitis Investigation

Type:

Public Health Announcements

Format:

Web Page

Keywords

AFM

Acute Flaccid Myelitis

MeSH

centers for disease control and prevention (U.S.)

Acute Flaccid Myelitis (AFM) is a rare but serious condition that peaks during the winter months. Here is a summary of what we know about it.

Free full text

View

CDC is concerned about AFM, a serious condition that causes weakness in the arms or legs.
From August 2014 through August 2018, CDC has received information on a total of 362 cases of AFM across the US; most of the cases continue to occur in children.
Even with an increase in cases since 2014, AFM remains a very rare condition. Less than one in a million people in the United States get AFM each year.
It’s always important to practice disease prevention steps, such as staying up-to-date on vaccines, washing your hands, and protecting yourself from mosquito bites.

Author/s:

Center for Disease Control and Prevention

Patient Education Resources from the CDC

Tracy Ashby — Thu, 01 Feb 2018 06:00:00 +0000

Date Added:

February 1, 2019

Publisher:

U.S. Department of Health & Human Services

URL:

Patient Education Resources from the CDC

Type:

Patient Education Materials

Format:

Web Page

Keywords

MeSH

centers for disease control and prevention (U.S.)

A good resource for patient education materials about prevention of heart attaks and strokes.

Free full text

View

Mission

"CDC works 24/7 to protect America from health, safety and security threats, both foreign and in the U.S. Whether diseases start at home or abroad, are chronic or acute, curable or preventable, human error or deliberate attack, CDC fights disease and supports communities and citizens to do the same.

CDC increases the health security of our nation. As the nation’s health protection agency, CDC saves lives and protects people from health threats. To accomplish our mission, CDC conducts critical science and provides health information that protects our nation against expensive and dangerous health threats, and responds when these arise."

https://www.cdc.gov/about/organization/mission.htm